Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cariprazine in acute exacerbation of schizophrenia
NCT05368558Phase 3Terminated
- Sponsor
- AbbVie Inc.
- Start
- Aug 2022
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of cariprazine in schizophrenia, sponsored by AbbVie Inc.. Started Aug 2022; status: terminated.
02
Drugs
cariprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05368558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05368558.